HOME > Products and Technologies > Publications
  • Lee et al., Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles:
        implication for gene therapy of ischemic diseases., Biochemical and Biophysical Research Communications,
        2000;272:230-235.
  • Carlsson et al., Quantitative MR measurements of regional and global left ventricular function and strain after
        intramyocardial transfer of VM202 into infarcted swine myocardium., American journal of physiology - Heart and
        Circulatory Physiology, 2008;295:H522-532.

  • Cho et al., Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a
        porcine acute myocardial infarction model., European Journal of Cardio-thoracic Surgery, 2008;34:857-863.

  • Saeed et al., MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a
        new plasmid human hepatocyte growth factor in ischemic swine myocardium., Radiology, 2008;249:107-118.

  • Pyun et al., Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a
        rabbit model of limb ischemia., Gene Therapy, 2010;17:1442-1452.

  • Saeed et al., Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy of hepatocyte growth
        factor gene in chronic infarct scar., Cardiovascular Revascularization Medicine, 2011;12:111-122.

  • Perin et al., Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection in a pig model of
        chronic myocardial ischemia., Journal of Cardiac Failure, 2011;17:601-611.

  • Hahn et al., Enhanced cardio-protective effects by coexpression of two isoforms of hepatocyte growth factor from naked
        plasmid DNA in a rat ischemic heart disease model., The Journal of Gene Medicine, 2011;13:549-555.
  • Henry et al., Safety of a non-viral plasmid-encoding dual isoforms of heypatocyte growth factor in critical limb ischemia
        patients: a phase I study., Gene Therapy,  2011;18:788-794.

  • Gu et al., A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with
        critical limb ischemia., The Journal of Gene Medicine, 2011;13:602-610.

  • Kim et al., Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study., Gene
        Therapy, 2013;20:717-722.

  • Ajroud‐Driss et al., Phase 1/2 Open-Label Dose-Escalation Study of Plasmid DNA Expressing Hepatocyte Growth Factor in
        Patients with Painful Diabetic Neuropathy, Molecular Therapy, 2013;21:1279-1286.

  • Kessler et al., Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy, Annals of Clinical and
        Translational Neurology, 2015;2:465-478.

  • Kibbe et al., Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with
        critical limb ischemia., Gene Therapy, 2016;3:306-312.

  • Robert L. Sufit et al., Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.,
        Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017 May;18(3-4):269-27.
  • Kim et al., Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against
        Her-2/neu antigen., Int. J. Cancer, 2002;102:428–434.

  • Lee et al., Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but
        comparable CTL activity in mice., Vaccine,  2003;21:521–531.

  • Chang et al., Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants., Int. J. Cancer,
        2004;111:86-95.

  • Ko et al., Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.,
        Gene Therapy,  2008;15:1351-1360.
  • Jung et al., Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed
        mutagenesis., Biochemical and Biophysical Research Communications, 2011;405:399-404.
  • Shikai Wu et al., Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent
        chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy., Support Care Cancer,
        2012;20:1875-1884.
  • Park et al., Control of IgE and selective T(H)1 and T(H)2 cytokines by PG102 isolated from Actinidia arguta., J Allergy Clin
        Immunol, 2005;116:1151-1157.

  • Chen et al., Evaluation of IgE binding to proteins of hardy (Actinidia arguta), gold (Actinidia chinensis) and green
        (Actinidia deliciosa) kiwifruits and processed hardy kiwifruit concentrate, using sera of individuals with food allergies to
        green kiwifruit., Food and Chemical Toxicology, 2006;44:1100–1107.

  • Park et al., Suppression of spontaneous dermatitis in NC/Nga murine model by PG102 isolated from Actinidia arguta.,
        J Invest Dermatol, 2007;127:1154-1160.

  • Hong et al., Subacute toxicological study of PG102, a water-soluble extract derived from Actinidia arguta, in SD rats.,
        Korean J Vet Res, 2008;48:413-421.

  • Choi et al., Blockade of Atopic Dermatitis-like Skin Lesions by DA-9102, a Natural Medicine Isolated from Actinidia arguta,
        in the Mg-deficiency Induced Dermatitis Model of Hairless Rats. Exp Biol Med. , 2008;233:1026-34.

  • Kim et al., Anti-allergic effects PG102, a water-soluble extract prepared from Actinidia arguta, in a murine OVA-induced
        asthma model., Clin Exp Allergy, 2009;39:280-289.

  • Kim et al., Suppression of allergic diarrhea in murine OVA-induced food allergy model by PG102, a water-soluble extract
        prepared from Actinidia arguta., International Archives of Allergy and Immunology, 2009;150:164-171.

  • Ho et al., Effect of PG102, a Water-soluble Extract from Actinidia arguta on Canine Atopic Dermatitis.,
        Kor. J. Pharmacogn, 2009;40: 59-64.
  • Marsella et al., A randomized, double-blind, placebo-controlled study to evaluate the effect of EFF1001 (PG102), an
        Actinidia arguta (hardy kiwi) preparation, on CADESI score and pruritus in dogs with mild to moderate atopic dermatitis.,
        Veterinary Dermatology, 2010;21:50-57.

  • Kim et al., The effects of PG102, a water soluble extract from Actinidia arguta, 1 on serum total IgE 2 levels; A double-
        blind, randomized, placebo-controlled exploratory clinical study., European Journal of Nutrition, 2011;50:523-529.
        

  • Kim et al., Reconstitution of anti-allergic activities of PG102 derived from Actinidia arguta by combining synthetic
        chemicalcompounds. Exp Biol Med. 2013;238(6):631-40.
  • Shin et al., Suppressive Effects of PG201, an Ethanol Extract from Herbs, on Collagen Induced Arthritis in Mice.,
        Rheumatology, 2003,42:665-672.

  • Park et al., Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-
        induced arthritis in rabbits., Biochemical and Biophysical Research Communications, 2005,331:1469-1477.

  • Choi et al., Suppressive effects of PG201, an antiarthritic botanical formulation, on lipopolysaccharide-induced
        inflammatory mediators in Raw264.7 cells., Experimental Biology and Medicine, 2012,237:499-508.

  • Choi et al., PG201 downregulates the production of nitrite by upregulating heme oxygenase-1 expression through the
        control of phosphatidylinositol 3-kinase and NF-E2-related factor 2. Nitric Oxide, 2013,33C:42-55.
  • Kang, et al., A double-blind, randomized, placebo-controlled exploratory clinical study to assess the efficacy, dose
        responses, and safety of PG201 in patients with osteoarthritis of the knee., 2012, Submitted for publication
        (Phase II study in Korea)

  • Yoo et al., Efficacy and safety of PG201 and celecoxib in the treatment of symptomatic knee osteoarthritis; A double
        blinded, randomized, multi-center, active drug comparative, parallel-group non-inferiority, phase III study. Rheumatology
        International, 2014,34:1369-1387.
  • Lee, et al., Ameliorating effects of HX106N, a water-soluble botanical formulation, on Aβ25-35-induced memory
        impairment and oxidative stress in mice. Biological and Pharmaceutical Bulletin, 2014; 37(6): 954-60

  • Lee, et al., Effects of HX106N, a water-soluble botanical formulation on scopolamine-induced memory impairment in
        mice. Korean J Food Nutr., 2014; 27:673-77

  • Lee, et al., Effective suppression of nitric oxide production by HX106N through transcriptional control of heme
        oxygenase-1. Experimental Biology and Medicine, 2015; 240(9):1136-46
  • Kwon, et al., Effects of the Combination Herbal Extract on Working Memory and White Matter Integrity in Healthy
        Individuals with Subjective Memory Complaints : A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.,
        Korean J Biol Psychiatry, 2015;22(2):63-77.
  • Choi, et al., A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in
        a high fat diet-induced obesity mouse model, Biochem Biophys Res Commun, 2007;359(3):419-25.

  • Lee, et al., Dehydrodiconiferyl alcohol isolated from Cucurbita moschata shows anti-adipogenic and anti-lipogenic effect in
        3T3-L1 cells, Journal of Biological Chemistry, 2012;287(12):8839-51.

  • Lee, et al., Upregulation of heme oxygenase-1 expression by dehydrodiconiferyl alcohol (DHCA) through the AMPK-Nrf2
        dependent pathway, Toxicology and Applied Pharmacology, 2014;281(1): 87–100.

  • Lee, et al., Effective suppression of pro-inflammatory molecules by DHCA via IKK-NF-κB pathway, in vitro and in vivo,
        British Journal of Pharmacology, 2015;172(13):3353-69.

  • Lee, et al., Dehydrodiconiferyl alcohol (DHCA) modulates the differentiation of Th17 and Th1 cells and suppresses
        experimental autoimmune encephalomyelitis, Mol Immunol., 2015;68(2):434-44.
  •